Zobrazeno 1 - 10
of 62
pro vyhledávání: '"O Gojis"'
Autor:
Daniel Lythgoe, Waheeda Owadally, Sacha J Howell, Pippa Riddle, Iain R. Macpherson, Evandro de Azambuja, Carlo Palmieri, Rebecca Asher, Conrad Lewanski, Adam Januszewski, Barabara Stanley, Mark Beresford, Riz Ahmed, O Gojis, Felipe Ades Moraes, Deep Shah, Kelvin Yan
Publikováno v:
Cancer Research. 75:P4-15
Background: Neoadjuvant chemotherapy delivered with trastuzumab (NCT) has been shown to increase the rates of pathological complete response (pCR) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in
Autor:
Tma Abdel-Fatah, R. C. Coombes, Jacqui Shaw, Carlo Palmieri, Simak Ali, David Moore, Bharath Rudraraju, Ian O. Ellis, Andrew R. Green, O Gojis
Publikováno v:
Cancer Research. 72:P2-10
Introduction: Steroid receptor coactivator 3 (SRC3) acts as a coactivator of nuclear receptors including estrogen receptor-alpha (ER). SRC3 has been implicated in the pathogenesis of breast cancer (BC) as well as in resistance to endocrine therapy. S
Autor:
Tim Crook, Martino Monteverde, Ornella Garrone, O Gojis, N. Syed, Alastair M. Thompson, Laura Lattanzio, Marco Merlano, C. Lo Nigro, Mirella Fortunato, Carlo Palmieri, Bharath Rudraraju
Publikováno v:
British Journal of Cancer
Background: The CCAAT/enhancer binding protein delta (CEBPδ) is a member of a highly conserved family of basic region leucine zipper transcription factors. It has properties consistent with a tumour suppressor; however, other data suggest that CEBP
Autor:
Ornella Garrone, Rodolfo Brizio, Martino Monteverde, Carlo Palmieri, T Crook, C. Lo Nigro, Bharath Rudraraju, O Gojis, Laura Lattanzio, Marco Merlano, Nelofer Syed
Publikováno v:
British Journal of Cancer
Background: Calcium is an important intracellular messenger that mediates many biological processes that are relevant to the malignant process. Calcium ion channels are key in controlling the intracellular calcium, and little is known about their rol
Autor:
Carlo Palmieri, Bharath Rudraraju, Katy Hogben, Sami Sousha, Charles Coombes, Susan Cleator, Mihir Gudi, O Gojis
Publikováno v:
Nature Reviews Clinical Oncology. 7:83-89
Members of the nuclear receptor superfamily are ligand-regulated transcription factors involved in the control of a broad range of normal physiological and disease processes. The estrogen receptor alpha (ERalpha) is a member of the steriod receptor f
Autor:
Felipe Ades, Iain R. Macpherson, Deep Shah, Kelvin Yan, Rebecca Asher, Pippa Riddle, Barbara Stanley, Mark Beresford, Riz Ahmed, O Gojis, Daniel Lythgoe, Sacha J Howell, Evandro de Azambuja, Waheeda Owadally, Carlo Palmieri, Adam Januszewski, Conrad Lewanski
Publikováno v:
Palmieri, C, Macpherson, I R, Yan, K, Ades, F, Riddle, P, Ahmed, R, Owadally, W, Stanley, B, Shah, D, Gojis, O, Januszewski, A, Lewanski, C, Asher, R, Lythgoe, D, de Azambuja, E, Beresford, M & Howell, S J 2015, ' Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. ', Oncotarget . https://doi.org/10.18632/oncotarget.4801
Oncotarget
Europe PubMed Central
Oncotarget
Europe PubMed Central
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799065be6a2b508e81762598ad227cdd
https://www.research.manchester.ac.uk/portal/en/publications/neoadjuvant-chemotherapy-and-trastuzumab-versus-neoadjuvant-chemotherapy-followed-by-postoperative-trastuzumab-for-patients-with-her2positive-breast-cancer(4f3922f0-7b54-4782-84f9-fa861ff7fbc4).html
https://www.research.manchester.ac.uk/portal/en/publications/neoadjuvant-chemotherapy-and-trastuzumab-versus-neoadjuvant-chemotherapy-followed-by-postoperative-trastuzumab-for-patients-with-her2positive-breast-cancer(4f3922f0-7b54-4782-84f9-fa861ff7fbc4).html
Autor:
Wilbert Zwart, Simak Ali, Sander Canisius, Koen D. Flach, David Moore, Jacqui Shaw, Steve Y.T. Chan, Tarek M. A. Abdel-Fatah, Ingrid Hofland, Jason S. Carroll, O Gojis, Bharath Rudraraju, R. Charles Coombes, Marjolein Droog, Ian O. Ellis, Mark Opdam, Ekaterina Nevedomskaya, Carlo Palmieri
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(2)
Purpose: The steroid receptor coactivator SRC3 is essential for the transcriptional activity of estrogen receptor α (ERα). SRC3 is sufficient to cause mammary tumorigenesis, and has also been implicated in endocrine resistance. SRC3 is posttranslat
Autor:
O Gojis, Simon P. Langdon, Dana Faratian, C Stamp-Vincent, Charlie Gourley, David C. Wilson, Carlo Palmieri, Bharath Rudraraju
Publikováno v:
Palmieri, C, Gojis, O, Rudraraju, B, Stamp-Vincent, C, Wilson, D, Langdon, S, Gourley, C & Faratian, D 2013, ' Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance ', British Journal of Cancer, vol. 108, no. 10, pp. 2039-2044 . https://doi.org/10.1038/bjc.2013.199
British Journal of Cancer
British Journal of Cancer
Background: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c99420b88c309814884171ec1013126
https://hdl.handle.net/20.500.11820/be110ef3-373b-4c30-8e25-34c472275117
https://hdl.handle.net/20.500.11820/be110ef3-373b-4c30-8e25-34c472275117
Autor:
Robert C. F. Leonard, Tri Tat, Mihir Gudi, Andrew Porter, Carlo Palmieri, Susan Cleator, O Gojis, Jonathan Krell, Katy Hogben, Sami Shousha, Deep Shah, Pippa Riddle, Kevin Fox, Riz Ahmad, Stephanie Kirschke, R. Charles Coombes, Sarah Mahmoud
Publikováno v:
Clinical breast cancer. 11(2)
Background Adjuvant trastuzumab (AT) is known to significantly improve survival of women with HER2+ early breast cancer. This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant popula
Autor:
Qunyan Yu, Eric Lam, Jun Wang, Stephanie K. Guest, David Peston, R. Charles Coombes, O Gojis, Janna Krol, Richard E. Francis, Piotr Sicinski, Ursula B. McGovern, Barrie Peck, Carlo Palmieri, Sami Shousha, Johan Hartman, Stephen S. Myatt, Aleksandra Filipovic
Publikováno v:
International journal of oncology. 35(1)
The tyrosine kinase receptor, HER2 is a crucial prognostic marker and therapeutic target for breast cancer; however, the downstream targets and biological effectors of HER2 remain unclear. We investigated the relationship between HER2 and the transcr